Myocardial biomarkers in coronary microvascular dysfunction: Response to ranolazine
These findings suggest that higher u-hs-TnI signals greater ischemia improvement on ranolazine. Further studies evaluating ischemia therapies in CMD are needed to develop potential HFpEF prevention targets.
Authors
- Katherine Hampilos (ORCID: https://orcid.org/0000-0003-0739-8077)
- Janet Wei (ORCID: https://orcid.org/0000-0002-1311-618X)
- Michael D. Nelson (ORCID: https://orcid.org/0000-0002-3232-8639)
- Galen Cook‐Wiens (ORCID: https://orcid.org/0000-0003-4088-6240)
- Puja K. Mehta (ORCID: https://orcid.org/0000-0002-5678-812X)
- C. Noel Bairey Merz (ORCID: https://orcid.org/0000-0002-9933-5155)
- Anum Asif (ORCID: https://orcid.org/0000-0001-8241-5063)
- Carl J. Pepine
- Daniel S. Berman
Institutions
- Cedars-Sinai Medical Center (US)
- Emory University (US)
- The University of Texas at Arlington (US)
- University of Florida (US)
- S. Mark Taper Foundation (US)
- Cedars-Sinai Smidt Heart Institute (US)
- Imaging Center (US)
- The University of Texas at San Antonio (US)
Publication Details
- Journal
- American Heart Journal Plus Cardiology Research and Practice
- Published
- 2025-02-21
- DOI
- https://doi.org/10.1016/j.ahjo.2025.100513
- Primary Topic
- Cardiac electrophysiology and arrhythmias
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- U.S. Department of Defense
- Gustavus and Louise Pfeiffer Research Foundation
- National Heart, Lung, and Blood Institute
- National Center for Advancing Translational Sciences